Unfortunately, traditional tumor markers, such as cytokeratin fragment 21–1 (CYFRA21-1), pro-gastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), and neuron-specific enolase (NSE), are limited in clinical use due to their poor sensitivity and specificity values [6–8]. The gene discussed is GRP; the disease is neoplasm.